Literature DB >> 16791744

Influence of dopamine deficiency in early Parkinson's disease on the slow stimulation multifocal-ERG.

Anja M Palmowski-Wolfe1, Maria Timoner Perez, Stefanie Behnke, Gerhard Fuss, Martin Martziniak, Klaus W Ruprecht.   

Abstract

PURPOSE: In animal studies intravitreal injection of tetrodotoxin (TTX) results in mfERG waveform changes similar to those observed in glaucoma. As TTX blocks amacrine as well as ganglion cells, there is still a question regarding the underlying cell population responsible for these changes in waveform. In an attempt to assess the contribution of the amacrine cells to these changes, a mfERG was obtained from patients with Parkinson's disease as some amacrine cells are mediated by dopamine, a substance lacking in Parkinson's.
METHODS: Eight patients with early Parkinson's disease underwent ophthalmologic examination, testing of contrast sensitivity and electrophysiological examination according to ISCEV standard at least 12 h following their last medication with Dopamine. A slow stimulation mfERG was obtained with a stimulus base interval of 53.3 ms and with a stimulus base interval of 106.6 ms. During MF-ERG recordings 103 hexagons stimulated the central 50 deg of the retina simultaneously and independently (m-sequence 2(13), L(max): 200 cd/m(2), approximately 100% contrast).
RESULTS: Contrast sensitivity and ISCEV standard electrophysiological testing was unremarkable. When the mfERG was analyzed, only four patients had an adequate signal-to-noise ratio to allow further data analysis - one of whom was diagnosed with a multi system atrophy in retrospect. The first order response component was analyzed at a filter setting of 10-300 Hz and at 100-300 Hz (OPs) and compared to mfERGs of a control group. On average, in patients, the amplitude of N1P1 was slightly lower in the central and nasal response averages. When the three OPs at a latency of 72-89 ms were analyzed in the 53.3 ms base interval recording, the most marked difference in amplitude was observed in the superior nasal response average of the first OP. Here a mean amplitude of 1.3 nV/deg(2) in patients compared to a mean amplitude of 1.9 nV/deg(2) in the control group (P: 0.08). DISCUSSION: In contrast to our previous findings in NTG, there was a consistent presence of three OPs. Under the stimulus conditions applied, we did not find an influence of dopaminergic amacrine cells on the mfERG in our patients with moderate stages of Parkinsion's. The difficulties in obtaining an adequate signal-to noise ratio due to e.g. muscle artifacts even in Parkinson patients of moderate disease stages render a success of mfERG recording in patients with more advanced stages unlikely. The question of the influence of dopaminergic amacrine cells on the mfERG could possibly be addressed using MPDT in animal research.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16791744     DOI: 10.1007/s10633-006-0008-8

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  26 in total

1.  The optic nerve head component of the human ERG.

Authors:  E E Sutter; M A Bearse
Journal:  Vision Res       Date:  1999-02       Impact factor: 1.886

2.  Regional variations in local contributions to the primate photopic flash ERG: revealed using the slow-sequence mfERG.

Authors:  Nalini V Rangaswamy; Donald C Hood; Laura J Frishman
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-07       Impact factor: 4.799

3.  The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D1 and D2 receptor ligands on the pattern electroretinogram.

Authors:  I Bodis-Wollner; A Tzelepi
Journal:  Vision Res       Date:  1998-05       Impact factor: 1.886

4.  ERG campimetry using a multi-input stimulation technique for mapping of retinal function in the central visual field.

Authors:  U Kretschmann; K Rüther; T Usui; E Zrenner
Journal:  Ophthalmic Res       Date:  1996       Impact factor: 2.892

5.  Outer retinal dysfunction in patients treated with vigabatrin.

Authors:  C F Arndt; P Derambure; S Defoort-Dhellemmes; J C Hache
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

6.  [Multifocal electroretinogram (MF-ERG) in diagnosis of macular changes. Example: senile macular degeneration].

Authors:  A M Palmowski; E E Sutter; M A Bearse; W Fung
Journal:  Ophthalmologe       Date:  1999-03       Impact factor: 1.059

7.  Evidence for a ganglion cell contribution to the primate electroretinogram (ERG): effects of TTX on the multifocal ERG in macaque.

Authors:  D C Hood; L J Frishman; S Viswanathan; J G Robson; J Ahmed
Journal:  Vis Neurosci       Date:  1999 May-Jun       Impact factor: 3.241

8.  Das multifokale elektroretinogramm in der diagnostik und verlaufskontrolle lokalisierter Netzhautfunktionsstörungen: fallbericht eines patienten mit chorioretinopathia centralis serosa.

Authors:  A M Palmowski; E E Sutter; M A Bearse; W Fung
Journal:  Ophthalmologica       Date:  1999       Impact factor: 3.250

9.  Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study.

Authors:  H Ikeda; G M Head; C J Ellis
Journal:  Vision Res       Date:  1994-10       Impact factor: 1.886

10.  Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss?

Authors:  A Peppe; P Stanzione; M Pierantozzi; R Semprini; A Bassi; A M Santilli; R Formisano; M Piccolino; G Bernardi
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1998-04
View more
  2 in total

1.  Correlations among multifocal electroretinography and optical coherence tomography findings in patients with Parkinson's disease.

Authors:  Metin Unlu; Duygu Gulmez Sevim; Murat Gultekin; Cagatay Karaca
Journal:  Neurol Sci       Date:  2018-01-18       Impact factor: 3.307

2.  The Contribution of L-Type Cav1.3 Channels to Retinal Light Responses.

Authors:  Liheng Shi; Janet Ya-An Chang; Fei Yu; Michael L Ko; Gladys Y-P Ko
Journal:  Front Mol Neurosci       Date:  2017-12-05       Impact factor: 5.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.